We are live on ! Find out more

STAAR Surgical

STAA

Market cap $1.27B

25.24 USD

+0.63

2.56%

At close Updated Oct 29, 4:00 PM EDT

Pre-market

After hours

25.12

-0.12

0.48%

1 day

2.56%

5 days

12.33%

1 month

12.53%

3 months

5.74%

6 months

-0.94%

Year to date

6.95%

1 year

-5.08%

5 years

-78.69%

10 years

198.7%

About: Staar Surgical Co is a manufacturer of lenses. It designs, develops, manufactures, and sells implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. The company offers two types of products: Implantable Collamer lenses (ICL), which are used in refractive surgery. The company generates almost all of its revenue from the sale of its ICL products. Geographically, the company generates key revenue from Foreign sales.

Employees: 957

Healthcare Medical Instruments & Supplies

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 27.3%

Neutral 63.6%

Negative 9.1%

STAAR Surgical Appoints Pascal Aeschlimann as Vice President of Asia Pacific

LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (“STAAR” or the “Company”) (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced the appointment of Pascal Aeschlimann as Vice President of Asia Pacific, effective November 2, 2026. Mr. Aeschlimann, who led STAAR's commercial expansion across Asia and the Middle East from 2002 to 2010, returns after more than a decade building and leading.

STAAR Surgical Appoints Pascal Aeschlimann as Vice President of Asia Pacific

Zacks Investment Research

Earnings Preview: Staar Surgical (STAA) Q3 Earnings Expected to Decline

Staar Surgical (STAA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Staar Surgical (STAA) Q3 Earnings Expected to Decline

STAAR Surgical to Participate in Upcoming Investor Conferences

LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO™ family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that Warren Foust, President and Chief Executive Officer, and Deborah Andrews, Executive Vice President and Chief Financial Officer, will participate in two investor conferences in November: Stifel 2026 Healthcare Conference Date: Tuesday, November 10, 2026 Location: New York, NY Fires.

STAAR Surgical to Participate in Upcoming Investor Conferences

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duties by Certain Officers and Directors of STAAR Surgical Company (NASDAQ: STAA)

NEW YORK, Oct. 21, 2026 /PRNewswire/ -- Levi & Korsinsky announces that it has commenced an investigation of STAAR Surgical Company (NASDAQ: STAA) concerning possible breaches of fiduciary duties. If you are a current shareholder of STAA, you can request additional information here: https://zlk.com/cases/staar-surgical-company-class-action-lawsuit-staa-3 or contact Joseph E.

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duties by Certain Officers and Directors of STAAR Surgical Company (NASDAQ: STAA)

STAAR Surgical to Host Third Quarter 2026 Earnings Results Call and Webcast on November 4, 2026

LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that it will release financial results and a letter to shareholders for the third quarter ended October 2, 2026, on Wednesday, November 4, 2026, after the market close. The Company will also host an earnings call and webcast at 5:30 p.m. ET that same day to discuss its financial results.

STAAR Surgical to Host Third Quarter 2026 Earnings Results Call and Webcast on November 4, 2026

STAAR Surgical Names Andrew Pilon as Vice President of Business Development

LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (“STAAR” or the “Company”) (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced the appointment of Andrew Pilon, O.D. as Vice President of Business Development. Dr. Pilon will report to STAAR President and Chief Executive Officer Warren Foust and will work closely with the Company's senior leadership team to capitalize on opportunities th.

STAAR Surgical Names Andrew Pilon as Vice President of Business Development

The Motley Fool

Why Staar Surgical Zoomed Almost 8% Higher on Tuesday

That pundit now believes it's a buy. He cited positive sales momentum, especially in a key market overseas.

Why Staar Surgical Zoomed Almost 8% Higher on Tuesday

This Staar Surgical Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

This Staar Surgical Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday

The Motley Fool

Why Staar Surgical Stock Soared Today

It anticipates this will run for one year. The company's recent fundamentals have been rather impressive.

Why Staar Surgical Stock Soared Today

STAAR Surgical Board Approves $50 Million Share Repurchase Authorization

LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO™ family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that its Board of Directors, at a regularly scheduled meeting, authorized a share repurchase program under which the Company may repurchase up to $50 million of its outstanding common stock. Under its buyback program, STAAR may repurchase shares in the open market, through privately ne.

STAAR Surgical Board Approves $50 Million Share Repurchase Authorization

See News Rankings

Price charts implemented using Lightweight Charts™